[Prostatitis syndrome].
Prostatitis syndrome is a multifactorial disease with a largely unknown etiology. Quite different therapeutic options are therefore recommended. According to the new NIH classification, pathogens can be cultured only in acute and chronic bacterial prostatitis. A long-term antimicrobial therapy, mainly with fluoroquinolones, is then recommended. Most patients suffer from chronic pelvic pain syndrome (CP/CPPS) which can be subdivided into inflammatory and non-inflammatory types. Whether the inflammatory CP/CPPS is an infectious disease remains uncertain. The effect of an antibiotic therapy therefore remains debatable. In case of proven or suspected functional infravesical obstruction, treatment with a-receptor blockers is recommended. Accompanying symptomatic therapy is also recommended. It is important, however, to keep the patient fully informed about the diagnostic and therapeutic limitations.
Wagenlehner
Florian M E
FM
Klinik und Poliklinik für Urologie und Kinderurologie, Justus-Liebig-Universität Giessen. Wagenlehner@AOL.com
Schneider
H
H
Weidner
W
W
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000892:Anti-Infective Agents, Urinary / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D002908:Chronic Disease; D003937:Diagnosis, Differential; D024841:Fluoroquinolones / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D017699:Pelvic Pain / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D011472:Prostatitis / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D013577:Syndrome
D000317:Adrenergic alpha-Antagonists; D000892:Anti-Infective Agents, Urinary; D024841:Fluoroquinolones